HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

CD133+CD34+ stem cells are mobilized after musculoskeletal surgery and target endothelium activated by surgical wound fluid.

AbstractPURPOSE:
CD133+CD34+ hematopoietic stem cells (HSCs) have been shown to differentiate into cell types of nonhematopoietic lineage. It is unclear whether HSCs target and repair damaged musculoskeletal tissue. We aimed to analyze if HSCs are mobilized after musculoskeletal surgery to circulation, home to surgical wound fluid (SWF)-activated endothelium, and are chemoattracted by SWF under in vitro conditions.
METHODS:
Circulating HSC levels were measured at t = 3, 8, 24, 48 h postoperatively using fluorescence-activated cell sorting (FACS) and compared with preoperative levels (t = 0) and normal volunteers. For adhesion experiments, HSCs were incubated on SWF-activated human umbilical vein endothelial cells (HUVECs) and HSC/HUVEC ratios determined by FACS. Adhesion receptor expression on HSC (L-selectin, lymphocyte function-associated antigen 1 (LFA-1), very late antigen-4) and SWF-activated HUVECs (P-selectin, E-selectin, V-cell adhesion molecules (CAM), I-CAM) was determined and HSC adhesion measured again after blocking upregulated receptors. Using a modified Boyden chamber, HSC chemotaxis was analyzed for an SWF and cytokine-neutralized SWF (vascular endothelial growth factor (VEGF), stromal-derived factor-1, interleukin-8) gradient.
RESULTS:
Circulating HSCs were significantly increased 8 h after surgery. Increasing HSC adhesion to HUVECs was shown for SWF isolated at any postoperative time point, and chemoattraction was significantly induced in an SWF gradient with SWF isolated 8 and 24 h postoperatively. Receptor and cytokine blockade experiments with monoclonal antibodies revealed decreased HSC adhesion to SWF-activated endothelium and showed lower chemotaxis after blocking the LFA-1-I-CAM-1 receptor axis (adhesion) and neutralizing VEGF-165 (chemotaxis).
CONCLUSIONS:
Our data demonstrate that HSCs are mobilized after trauma, target to wound-associated endothelium via the LFA-1-I-CAM-1 axis, and are chemoattracted by VEGF-165 under in vitro conditions.
AuthorsMaciej Janusz Powerski, Dirk Henrich, Anna Sander, Daniel Wastl, Kendra Ludwig, Ingo Marzi
JournalLangenbeck's archives of surgery (Langenbecks Arch Surg) Vol. 396 Issue 3 Pg. 379-87 (Mar 2011) ISSN: 1435-2451 [Electronic] Germany
PMID20213459 (Publication Type: Journal Article)
Chemical References
  • AC133 Antigen
  • Antigens, CD
  • Antigens, CD34
  • E-Selectin
  • Glycoproteins
  • Interleukin-8
  • P-Selectin
  • PROM1 protein, human
  • Peptides
  • Selectins
  • Vascular Endothelial Growth Factor A
  • L-Selectin
Topics
  • AC133 Antigen
  • Antigens, CD (immunology, metabolism)
  • Antigens, CD34 (immunology, metabolism)
  • Cell Differentiation (immunology, physiology)
  • Cell Separation
  • Cells, Cultured
  • Chemotaxis (immunology, physiology)
  • E-Selectin (immunology, metabolism)
  • Endothelium (immunology, metabolism)
  • Female
  • Flow Cytometry (methods)
  • Glycoproteins (immunology, metabolism)
  • Hematopoietic Stem Cell Transplantation (methods)
  • Humans
  • Interleukin-8 (immunology, metabolism)
  • L-Selectin (immunology, metabolism)
  • Male
  • Middle Aged
  • Musculoskeletal Diseases (blood, surgery)
  • Orthopedic Procedures (adverse effects, methods)
  • P-Selectin (immunology, metabolism)
  • Peptides (immunology, metabolism)
  • Selectins (immunology, metabolism)
  • Statistics, Nonparametric
  • Vascular Endothelial Growth Factor A (immunology, metabolism)
  • Wound Healing (immunology, physiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: